Status quo and countermeasure of clopidogrel resistance predicted by gene testing.
10.3760/cma.j.issn.1003-9406.2019.06.030
- Author:
Xiaosai ZHANG
1
;
Yan WANG
Author Information
1. Department of Neurology, the Affiliated Hospital of Qingdao University, Shandong 266071, China. Email: drwangyanqd@126.com.
- Publication Type:Journal Article
- MeSH:
Blood Platelets;
Clopidogrel;
Drug Resistance;
Genetic Testing;
Humans;
Platelet Aggregation Inhibitors;
Ticlopidine
- From:
Chinese Journal of Medical Genetics
2019;36(6):649-653
- CountryChina
- Language:Chinese
-
Abstract:
Clopidogrel is the cornerstone of antiplatelet therapy, but there are ethnic and individual differences in the suppression of platelets. Some patients regularly taking drugs still cannot prevent the recurrence of cardio- and cerebrovascular thrombosis, thereby manifest low drug reactivity, i.e., clopidogrel resistance. Genetic polymorphism is the main reason for individual difference. Genetic testing has been used for evaluating the efficacy of antiplatelet therapy, adjusting therapeutic plan, and predicting the risk of cardio- and cerebrovascular thromboembolic events by determining the genetic polymorphisms related with antiplatelet drugs. This article provides a review for the status quo and countermeasure of clopidogrel resistance predicted by gene testing.
